Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 26/10/18 at 11:06am

Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J offered hope with their HIV vaccine, Bristol-Myer’s Squibb amazed with outstanding results for their Opdivo and Yervoy combo.

Meanwhile the FDA presented a plan for worldwide harmonisation on generics as Brexit sparked anxiety in the UK when the head of the Healthcare Distributors Association (HDA) Martin Sawer suggested that individuals may have to personally stockpile drugs in the event of a no-deal Brexit.

Nevertheless our most popular story was covered the fact that jobs website Indeed named British pharma firm GlaxoSmithKline as the third best place to work in the UK.

Check out this week’s top 10 most popular stories on

10. UCB and Biogen's lupus drug falls short at Phase 2b

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment of moderately-to-severely active systemic lupus erythematosus (SLE) in adult patients during a Phase 2b trial.

9. Takeda's subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious in comparison to placebo in patients suffering from moderately to severely active ulcerative colitis (UC).

8. US FDA offers plan for global regulatory harmonisation for generic drugs

The US Food and Drug Administration (FDA) is offering a proposal to the International Council on Harmonisation (ICH) aimed at harmonising the scientific and technical standards of generic drugs.

7. Industry leaders warn public may have to stockpile medicines in case of no-deal Brexit

Martin Sawer, the executive director of the Healthcare Distribution Association (HDA) – formerly the British Association of Pharmaceutical Wholesalers (BAPW) – has told MPs that a no-deal Brexit would have a ‘catastrophic’ effect on the supply of medicines coming into the UK, as he suggested that members of the public may have to personally stockpile drugs.

6. Pfizer & Lilly's non-opioid drug reduces pain in osteoarthritis

Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of its co-primary endpoints in the treatment of osteoarthritis (OA).

5. Janssen's Tremfya maintains skin clearance after 3 years in plaque psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin clearance which was maintained after three years of treatment.

4. BMS' Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with Opdivo in combination with Yervoy, survived four years or more.

3. NICE rejects Elil Lilly's Verzenio for breast cancer in draft guidance

Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that it has decided not to recommend the drugmaker’s therapy Verzenio (abemaciclib) for use on the NHS.

2. J&J announce promising Phase 1/2a results for HIV vaccine

The world may be one step closer to discovering a preventative vaccine for HIV after American multinational Johnson & Johnson's announcement of promising early stage results for an experimental HIV vaccine at the 2018 HIV Research for Prevention Conference in Madrid, Spain.

1. GSK named third best UK workplace

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs website Indeed’s list of top rated workplaces in the private sector in Britain.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches